

# Emerging Stimulant Mortality Trends by Active Ingredient

Joshua Black PhD

Rocky Mountain Poison & Drug Safety

RADARS® System

**24 February 2021 – VA Stimulant Safety Summit**

# Funding Disclosures

Funding provided by Denver Health and Hospital Authority, a non-profit safety net hospital in Denver, CO, USA.

This work was performed by the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS<sup>®</sup>) System. The RADARS System operations are supported by subscriptions from pharmaceutical manufacturers, government and non-government agencies for surveillance, research, and reporting services. RADARS System is the property of DHHA, a political subdivision of the State of Colorado. No subscriber participated in the conception, analysis, drafting, or review of this work.

No other competing conflicts of interest are declared.

# Stimulant Mortality is Rising in the US

From 2012 to 2018 in the US, poisonings involving psychostimulants with abuse potential<sup>†</sup> rose 30% per year<sup>1</sup>


<sup>†</sup>However, this includes drugs with a large range in toxicities, from methylphenidate to methamphetamine

**Study Goal: Identify which substances (medical and illicit) are contributing to the rise of psychostimulant mortality**

# Study Design & Methodology

- Death certificates list specific drugs contributing to the death
- Drug Mentions with Involvement database (CDC)
  - List of drug-related terms in Part I, II, and Box 43 of certificate
- Identified all drug mentions for stimulant substances
  - Cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA), pseudoephedrine, amphetamine, methylphenidate, generic terms, other terms
  - Decedents can be in multiple groups
- Setting: All decedents in 50 states + DC; 2010-2017
- Poisson regression used to calculate age-adjusted annual rate ratios



# Total Deaths: 2010-2017



Substance Mentioned	Deaths
All Stimulant Related	130,640
Medical Stimulant <sup>†</sup> Related	8,586
Cocaine	77,045
Methamphetamine	49,648
Amphetamine	8,245
MDMA	817
Pseudoephedrine	615
Methylphenidate	295

<sup>†</sup>Any death involving one of: amphetamine, methylphenidate, atomoxetine, modafinil, dextroamphetamine, lisdexamphetamine

# Increasing Mortality over Time



Mortality related to medical stimulants is rising rapidly alongside illicit substances like cocaine and methamphetamine.


# Modelled Annual Increase in Rates

Substance Mentioned	2010 Deaths	2017 Deaths	Annual Rate Ratio <sup>†</sup> (95% CI)	P-value
All Stimulant Related	9,022	31,515	1.20 (1.19, 1.20)	<0.001
Medical Stimulant Related	445	2,081	1.22 (1.21, 1.24)	<0.001
Cocaine	6,405	18,127	1.16 (1.16, 1.17)	<0.001
Methamphetamine	2,309	13,116	1.27 (1.27, 1.28)	<0.001
Amphetamine	411	2,023	1.23 (1.22, 1.24)	<0.001
MDMA	87	223	1.22 (1.18, 1.26)	<0.001
Pseudoephedrine	49	126	1.15 (1.11, 1.19)	<0.001
Methylphenidate	29	47	1.07 (1.02, 1.13)	0.008

Annual Rate Ratio of 1.20 corresponds to a doubling in rate approximately every 4 years

<sup>†</sup>Age- and state-population adjusted year-over-year increase in rate

# Age Profile of Decedents



Higher percentage of deaths among 18 to 39 year old decedents for medical stimulants than for decedents related to cocaine or methamphetamine



# Sex and Race Profile of Decedents

Decedent Sex	Medical Stimulants, N (%)	Any Illicit Stimulant, N (%)
Female	3,138 (36.5%)	34,833 (27.8%)
Male	5,448 (63.5%)	90,676 (72.2%)

- Higher proportion of female decedents of medical stimulants than illicit stimulants
- Higher proportion of white decedents (and lower proportion of black decedents) of medical stimulants than illicit stimulants

Decedent Race <sup>†</sup>	Medical Stimulants, N (%)	Any Illicit Stimulant, N (%)
Asian or Pacific Islander	168 (2.0%)	2,402 (1.9%)
Black	362 (4.2%)	27,051 (21.6%)
Native American or Alaskan Native	154 (1.8%)	2,145 (1.7%)
White	7,902 (92.0%)	93,911 (74.8%)

<sup>†</sup>NCHS/Census Bridged Race

# Strengths and Limitations

- Strengths
  - All deaths in the 50 states & DC
  - Not limited by ICD-10 code classification
- Limitations
  - Changing medical examiner/coroner practice over time and jurisdiction
  - Concomitant drugs (e.g., opioids) not analyzed

# Conclusions

- Rise in overall stimulant mortality attributable to many different stimulant drugs
- Disparities observed between medical and illicit mortality
- Drug overdose epidemic extends beyond just opioids
- Ensure drug testing is comprehensive of medical stimulants
  - Particular need to ensure methamphetamine is differentiated from amphetamine, MDMA

**Thank you!**  
Joshua Black, PhD  
RADARS® System